GU Cancers
US Focus Meeting 2026
📍 Hyatt Regency Boston Harbor, 101 Harborside Dr, Boston, MA 02128
🗓️ August 14 - 15, 2026
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the GU Cancers Focus Meeting 2026, to be held on August 14 - 15, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing GU Cancers research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of GU Cancers US Focus Meeting 2026:
Toni K. Choueiri
Dana-Farber Cancer Institute, Boston, MA
Rana R. McKay
UC San Diego, CA
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
aimee.williams@md-education.com
Agenda & Faculty
August 14, 2026 | Day 1
Session I: Initial Systemic Treatment in RCC
Moderated by:
Michael Serzan
Dana-Farber Cancer Institute, Boston, MA
09:05 AM
Adjuvant Immunotherapy: Patient Selection and Implementation
Bradley A. McGregor
Dana-Farber Cancer Institute, Boston, MA
09:20 AM
IO Combination Strategies in Clear Cell RCC
Wenxin (Vincent) Xu
Dana-Farber Cancer Institute, Boston, MA
09:35 AM
Systemic Treatment Approaches for Variant Histologies
Sumanta K. Pal
City of Hope, Duarte, CA
09:50 AM
Case Discussion: Adjuvant IO Failure and Progression
Michael Serzan
Dana-Farber Cancer Institute, Boston, MA
Session II: Post-Progression Treatment of Advanced RCC
Moderated by:
Xin Gao
Massachusetts General Hospital, Boston, MA
10:40 AM
HIF2α Inhibition in RCC
Yu-Wei Chen
UC San Diego Health, CA
10:55 AM
VEGF TKI Selection and Sequencing
Thai Huu Ho
MUSC Health, Charleston, SC
11:10 AM
Toxicity Management: IO, VEGF, and HIF Inhibitors
Stephanie A. Berg
Dana-Farber Cancer Institute, Boston, MA
11:25 AM
Case Discussion: Treatment Options After IO and VEGF Failure
Xin Gao
Massachusetts General Hospital, Boston, MA
Session III: Perioperative Management of Muscle-Invasive Bladder Cancer
Moderated by:
Alexandra Drakaki
UCLA Health, Los Angeles, CA
01:40 PM
Bladder-Sparing Treatment Approaches
Kent W. Mouw
Dana-Farber Cancer Institute, Boston, MA
01:55 PM
Perioperative Immunotherapy Integration
Joaquim Bellmunt
Dana-Farber Cancer Institute, Boston, MA
02:10 PM
ctDNA in Perioperative Bladder Cancer
Matthew D. Galsky
Icahn School of Medicine at Mount Sinai, New York, NY
02:25 PM
Case Discussion: T3 MIBC with Positive ctDNA After Treatment
Alexandra Drakaki
UCLA Health, Los Angeles, CA
Session IV: Treatment Strategies of Metastatic Urothelial Cancer Treatment
Moderated by:
Mark N. Stein
Columbia University Irving Medical Center, New York, NY
04:00 PM
First-Line Treatment Selection: Chemo vs IO vs Maintenance
Jonathan E. Rosenberg
Memorial Sloan Kettering Cancer Center, New York, NY
04:15 PM
Molecular Testing and Targeted Therapy Implementation
Abhishek Tripathi
City of Hope, Duarte, CA
04:30 PM
ADC and Targeted Therapy Toxicity Management
Charlene Mantia
Dana-Farber Cancer Institute, Boston, MA
04:45 PM
Case Discussion: HER2+ Metastatic Disease Treatment Decisions
Mark N. Stein
Columbia University Irving Medical Center, New York, NY
August 15, 2026 | Day 2
Session V: Approach to Biochemical Recurrent Prostate Cancer
Moderated by:
David J. Einstein
Beth Israel Deaconess Medical Center, Boston, MA
09:05 AM
PSMA PET Imaging and Oligometastatic Treatment
Tyler Seibert
UC San Diego Health, CA
09:20 AM
High-Risk BCR: Definition and Treatment Approaches
Michael Hurwitz
Yale School of Medicine, New Haven, CT
09:35 AM
Systematic treatment approaches for BCR
EA
Kriti Mittal
UMass Chan Medical School, Worcester, MA
09:50 AM
Case Discussion: Oligometastatic BCR Treatment Selection
David J. Einstein
Beth Israel Deaconess Medical Center, Boston, MA
Session VI: Management of Metastatic Hormone-Sensitive Prostate Cancer
Moderated by:
Philip J. Saylor
Massachusetts General Hospital, Boston, MA
10:40 AM
Triple Therapy: Evidence and Implementation
David R. Wise
NYU Langone Medical Center, New York, NY
10:55 AM
Novel Triple Combinations: PARP, PSMA, and AKT Inhibitors
Praful Ravi
Dana-Farber Cancer Institute, Boston, MA
11:10 AM
ARSI Selection: Factors for Agent Choice
Daniel P. Petrylak
Yale School of Medicine, New Haven, CT
11:25 AM
Case Discussion: De Novo High Volume mHSPC with Adverse Genetics
Philip J. Saylor
Massachusetts General Hospital, Boston, MA
Session VII: Treatment Strategies for Metastatic Castration-Resistant Prostate Cancer
Moderated by:
Guru P. Sonpavde
Advent Health Cancer Institute, Orlando, FL
01:40 PM
Radiopharmaceutical Integration
Atish D. Choudhury
Dana-Farber Cancer Institute, Boston, MA
01:55 PM
Genetic Testing and PARP Inhibitor Treatment
Alok K. Tewari
Dana-Farber Cancer Institute, Boston, MA
2:10 PM
Neuroendocrine Prostate Cancer: Recognition and Treatment
Himisha Beltran
Dana-Farber Cancer Institute, Boston, MA
2:25 PM
Case Discussion: mCRPC Treatment Sequencing Decisions
Guru P. Sonpavde
Advent Health Cancer Institute, Orlando, FL
Session VIII: Novel Therapeutics in Genitourinary Cancers
Moderated by:
Daniel J. George
Duke Health, Durham, NC
04:00 PM
Novel Agents in RCC
David A. Braun
Yale School of Medicine, New Haven, CT
04:15 PM
Emerging Targeting in Urothelial Carcinoma
Vadim S. Koshkin
UCSF Health, San Francisco, CA
04:30 PM
Next Generation Treatments in Prostate Cancer
Atish D. Choudhury
Dana-Farber Cancer Institute, Boston, MA
04:45 PM
Case Discussion: Clinical Trial Enrollment and Patient Experience
Daniel J. George
Duke Health, Durham, NC
Aimee Williams
Project Manager
How long has Aimee Williams been in the business?
Aimee Williams has been with MD Education since 2022
About Aimee Williams
I joined MD Education in 2022 as a Project Manager, leveraging my background in events management and passion for high-quality results. After earning a degree in Events Management, I gained hands-on experience managing projects while living in Nashville, TN. Driven and detail-oriented, I thrive in fast-paced environments, ensuring projects meet the highest standards. An avid traveler, I bring creativity and open-mindedness to problem-solving and client relationships.
